PRA claims to be the only company in the world with full-service bioanalytical capabilities near its clinics to support rapid results from Phase I clinical studies in both the US and Europe. The added services at the Kansas lab are in addition to offering full-service bioanalytical capabilities in its Assen, The Netherlands, laboratory.
"Initially we will offer large molecule analysis via LC/MS/MS and ELISA but will add additional capabilities such as mesoscale discovery (MSD) and Flow Cytometry mirroring our services already in place in The Netherlands Laboratory," spokeswoman Laura Lawton told us.
She added that PRA has seen "the market grow in large molecules and there has been a corresponding increase in client demand with our large molecule services in our lab in The Netherlands."
"By expanding our services to large molecule bioanalysis, we can now support all types of clinical trials," said Chad Briscoe, PRA executive director, science & innovations, bioanalytical laboratories. "It is an important addition to our services because the contribution of large molecules in drug research and the development of biosimilars have increased rapidly over the past few years."
PRA's harmonized laboratory facilities in The Netherlands and the U.S. are situated close to the clinical facilities and are configured to fully support all clinical study requirements.
This is one of the first moves that PRA has made since merging with RPS in July.